Neuland Laboratories

Neuland Laboratories EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Neuland Laboratories (NEULANDLAB.NS) as of Nov 18, 2026 is 32.97. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 59.72 — a change of -44.78% (lower).

EV/EBIT

32.97

YoY

-44.78%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Neuland Laboratories is 2026 32.97 . EV/EBIT (Enterprise Value to EBIT) of Neuland Laboratories was 2025 59.72 . It decreases by -44.78% lower compared to the previous year.

The Neuland Laboratories EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
414.04 INR
Jan 1, 2020
216.29 INR
Jan 1, 2021
145.20 INR
Jan 1, 2022
165.67 INR
Jan 1, 2023
67.93 INR
Jan 1, 2024
39.08 INR
Jan 1, 2025
59.72 INR
Jan 1, 2026
32.97 INR
The Neuland Laboratories EV/EBIT history
YEAREV/EBITYoY
32.97-44.78%
59.72+52.82%
39.08-42.48%
67.93-59.00%
165.67+14.09%
145.20-32.87%
216.29-47.76%
414.04-22.03%
531.03+194.22%
180.49-26.25%
244.71-19.56%
304.21+6.94%
284.45+3,180.89%
8.67+93.53%
4.48+94.78%
2.30-77.16%
10.07+226.95%
3.08-20.82%
3.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuland Laboratories Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Neuland Laboratories's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Neuland Laboratories's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Neuland Laboratories's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Neuland Laboratories grows earnings faster than its peers.

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

EV/EBIT (Enterprise Value to EBIT) of Neuland Laboratories is 32.97 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Neuland Laboratories changed from 59.72 to 32.97, representing a -44.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Neuland Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neuland Laboratories

All Key Metrics — Neuland Laboratories